A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B.

Trial Profile

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2012

At a glance

  • Drugs Egaptivon pegol (Primary)
  • Indications Embolism and thrombosis; Von Willebrand disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 24 Mar 2012 Planned number of patients changed from 2 to 3 and additional trial location (Austria) added as reported by European Clinical Trials Database.
    • 02 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top